Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Amid a huge furore over unsafe implanted medical devices the US FDA has released new proposals that are cautious to the point of toothlessness – and wouldn’t affect most…
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
The Mitra-FR study, which found that Abbott’s MitraClip failed to improve patients’ health, has been contradicted spectacularly by Coapt. So which one is right?